Alfama

The founders of European start-ups Alfama and hemoCORM Ltd. are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.

The founders of European start-ups HemoCORM Ltd. and Alfama Inc. are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.

CO is produced naturally in the body as a result of the breakdown of heme oxygenase, an enzyme involved in...

More from Global Vision

More from In Vivo